JP5991974B2 - 新規アミノピラゾロキナゾリン - Google Patents

新規アミノピラゾロキナゾリン Download PDF

Info

Publication number
JP5991974B2
JP5991974B2 JP2013520164A JP2013520164A JP5991974B2 JP 5991974 B2 JP5991974 B2 JP 5991974B2 JP 2013520164 A JP2013520164 A JP 2013520164A JP 2013520164 A JP2013520164 A JP 2013520164A JP 5991974 B2 JP5991974 B2 JP 5991974B2
Authority
JP
Japan
Prior art keywords
alkyl
independently
cycloalkyl
compound according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013520164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532652A5 (enExample
JP2013532652A (ja
Inventor
マティアス トゥロイ
マティアス トゥロイ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5991974(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2013532652A publication Critical patent/JP2013532652A/ja
Publication of JP2013532652A5 publication Critical patent/JP2013532652A5/ja
Application granted granted Critical
Publication of JP5991974B2 publication Critical patent/JP5991974B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2013520164A 2010-07-23 2011-07-22 新規アミノピラゾロキナゾリン Active JP5991974B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10170683 2010-07-23
EP10170683.6 2010-07-23
PCT/EP2011/062683 WO2012010704A1 (en) 2010-07-23 2011-07-22 New aminopyrazoloquinazolines

Publications (3)

Publication Number Publication Date
JP2013532652A JP2013532652A (ja) 2013-08-19
JP2013532652A5 JP2013532652A5 (enExample) 2015-09-03
JP5991974B2 true JP5991974B2 (ja) 2016-09-14

Family

ID=43037625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013520164A Active JP5991974B2 (ja) 2010-07-23 2011-07-22 新規アミノピラゾロキナゾリン

Country Status (23)

Country Link
US (1) US8735386B2 (enExample)
EP (1) EP2595987B1 (enExample)
JP (1) JP5991974B2 (enExample)
KR (1) KR20130132394A (enExample)
CN (1) CN103097388A (enExample)
AP (1) AP2012006640A0 (enExample)
AR (1) AR082850A1 (enExample)
AU (1) AU2011281504A1 (enExample)
BR (1) BR112013000107A2 (enExample)
CA (1) CA2803467A1 (enExample)
CL (1) CL2012003745A1 (enExample)
CO (1) CO6670575A2 (enExample)
EA (1) EA201201661A1 (enExample)
EC (1) ECSP13012448A (enExample)
GE (1) GEP20156289B (enExample)
MA (1) MA34389B1 (enExample)
MX (1) MX2013000821A (enExample)
PE (1) PE20131143A1 (enExample)
PH (1) PH12013500152A1 (enExample)
SG (1) SG187548A1 (enExample)
TW (1) TW201217380A (enExample)
UY (1) UY33526A (enExample)
WO (1) WO2012010704A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110585A1 (en) 2012-01-23 2013-08-01 Boehringer Ingelheim International Gmbh 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
ES2724331T3 (es) * 2013-11-15 2019-09-10 Oncoceutics Inc 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso
MD3805222T2 (ro) 2015-01-30 2025-04-30 Oncoceutics Inc Derivați de 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sărurile acestora și utilizarea acestora în terapie
WO2016180843A1 (en) * 2015-05-13 2016-11-17 Boehringer Ingelheim International Gmbh New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolin-2- yl)-(1 h-pyrazol-3-yl)-amines and derivatives as igf-1 r/ir inhibitors
CA3039012C (en) 2016-11-11 2021-08-24 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof
JP6915907B2 (ja) * 2017-05-26 2021-08-04 江▲蘇▼新元素医▲薬▼科技有限公司Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. 尿酸排泄を促進するurat1阻害剤
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
CN111566101B (zh) * 2018-04-24 2023-08-11 上海海雁医药科技有限公司 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
SG11202109443QA (en) 2018-11-02 2021-09-29 Fount Bio Inc Crosslinked materials
WO2020160321A1 (en) * 2019-01-30 2020-08-06 Yale University Compounds, compositions, and methods for treating fibrosis
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
MX2021010669A (es) * 2019-03-07 2021-09-28 BioNTech SE Proceso para la preparacion de una imidazoquinolina sustituida.
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
BR112021020951A2 (pt) * 2019-04-19 2021-12-14 Fount Bio Inc Dispensação e retenção de agentes ativos dentro da pele
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク. 線維芽細胞増殖因子受容体キナーゼの阻害剤
CN111960974A (zh) * 2020-08-28 2020-11-20 山东潍坊润丰化工股份有限公司 一种烯草酮中间体的合成方法
WO2022166725A1 (zh) * 2021-02-08 2022-08-11 南京明德新药研发有限公司 5,6-二氢噻吩并[3,4-h]喹唑啉类化合物
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856001B1 (en) * 1995-10-02 2002-08-28 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c receptor antagonists
EA010904B1 (ru) 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法

Also Published As

Publication number Publication date
KR20130132394A (ko) 2013-12-04
EA201201661A1 (ru) 2013-07-30
WO2012010704A1 (en) 2012-01-26
AP2012006640A0 (en) 2012-12-31
AU2011281504A1 (en) 2013-01-10
BR112013000107A2 (pt) 2016-05-17
CO6670575A2 (es) 2013-05-15
TW201217380A (en) 2012-05-01
EP2595987A1 (en) 2013-05-29
JP2013532652A (ja) 2013-08-19
MX2013000821A (es) 2013-05-30
CL2012003745A1 (es) 2013-05-31
PH12013500152A1 (en) 2013-02-18
UY33526A (es) 2012-02-29
AR082850A1 (es) 2013-01-16
EP2595987B1 (en) 2018-04-18
MA34389B1 (fr) 2013-07-03
CA2803467A1 (en) 2012-01-26
ECSP13012448A (es) 2013-03-28
US8735386B2 (en) 2014-05-27
SG187548A1 (en) 2013-03-28
CN103097388A (zh) 2013-05-08
GEP20156289B (en) 2015-05-25
US20120238542A1 (en) 2012-09-20
PE20131143A1 (es) 2013-10-23

Similar Documents

Publication Publication Date Title
JP2013532652A (ja) 新規アミノピラゾロキナゾリン
JP5809288B2 (ja) Igf1r受容体阻害薬としてのオキシインドールピリミジン
JP5871896B2 (ja) B−rafキナーゼインヒビター
JP5863058B2 (ja) 1H−イミダゾ[4,5−c]キノリン
JP6128133B2 (ja) Igf−1r/ir阻害剤としての5,8−ジヒドロ−6h−ピラゾロ[3,4−h]キナゾリン
JP5871897B2 (ja) ピリジルトリアゾール
JP5959754B2 (ja) トリアゾロピラジン
JP6370368B2 (ja) Brd4阻害剤としてのインドリノン類似体
JP6370376B2 (ja) Brd4阻害薬としてのトリアゾロピラジン誘導体
JP5850952B2 (ja) セリン/スレオニンキナーゼ阻害剤としての新しいアザインドリルフェニルスルホンアミド
JP6453845B2 (ja) Brd4阻害薬としてのジヒドロキナゾリノン類似体
JP5860031B2 (ja) Pdk1阻害薬としてのヘテロ環式カルボン酸アミド
JP5824068B2 (ja) セリン/トレオニンキナーゼ阻害剤としての新規トリアゾリルフェニルスルホンアミド
JP6085873B2 (ja) トリアゾロピリダジン
JP6488367B2 (ja) ベンゾイミダゾール誘導体
JP2014503573A (ja) セリン/スレオニンキナーゼ阻害薬としての新規ピリミド[5,4−d]ピリミジルアミノフェニルスルホンアミド
HK1180313A (en) New aminopyrazoloquinazolines
TW201307321A (zh) 新苯甲基羥吲哚嘧啶

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140709

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150430

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160816

R150 Certificate of patent or registration of utility model

Ref document number: 5991974

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250